Ardelyx, Inc.

NASDAQ:ARDX

Biotechnology

Healthcare
$3.12 -1.03%

-$0.06 today

Market cap
$784.28M
Beta
0.58
P/E (TTM)
-24.5
EPS (TTM)
-$0.24
52W Low $3.49High $8.40

Volume 4.75M

Average 3.58M

ARDX Pre-Tax Margin

Income before tax as a percentage of revenue.

Ardelyx, Inc.NASDAQ: ARDX

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin widens to -39.8%

Pre-tax margin was -39.8% in Q1 FY2026, up 14.6 pp from a year earlier. On a trailing-twelve-month basis it was -13.5%, up 1.0 pp year over year. Over 3 fiscal years it widened by 114.0 pp.

Context

  • Pre-tax margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-39.8%-39.5 pp QoQ
Last fiscal yearDec 2025
-14.9%-3.2 pp YoY
LTMMar 2026
-13.5%+1.0 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+14.6 pp——
1 year-3.2 pp——
3 years+114.0 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-14.9%
Year-over-year change
-3.2pp

Pre-Tax Margin vs competitors

How ARDX compares with its peers on the latest reported figures

  • ARDX's LTM Mar 2026 pre-tax margin of -13.5% is the 3rd highest of the 4 companies compared; the peer median is -8.1%.
  • Its year-over-year change of +1.0 pp is the 3rd highest of 4, against a peer median of +16.4 pp.
  • Over three fiscal years its change of +114.0 pp compares with a peer median of +59.0 pp.
ARDX Competitors Peer median
Pre-Tax Margin for ARDX and competitors
Company Period LTM level YoY 3-year change
XERSXeris Biopharma Holdings, Inc.LTM Mar 20263.8% +25.2 pp+87.3 pp
AKBAAkebia Therapeutics, Inc.LTM Mar 2026-8.1% +16.4 pp+30.6 pp
ARDXArdelyx, Inc.LTM Mar 2026-13.5% +1.0 pp+114.0 pp
MAZEMaze Therapeutics, Inc.LTM Mar 2026-612.7% -644.4 pp—
DMACDiaMedica Therapeutics Inc.FY2025— ——
Peer median (excluding ARDX) -8.1%+16.4 pp+59.0 pp

Competitors are the stored peer set for ARDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.1M52.16M124.46M333.62M407.32M
Cost of Revenue1M4.12M17.8M50.56M42.6M
Gross Profit9.1M48.04M106.66M283.06M364.72M
Gross Margin90.1%92.1%85.7%84.8%89.5%
Research & Development91.14M35.2M35.54M52.32M68.47M
Selling, General & Admin72.3M76.6M134.4M258.69M337.23M
Operating Expenses163.44M111.8M169.94M311.01M405.7M
Depreciation & Amortization2.81M1.14M1.29M2.06M3.06M
EBITDA(150.85M)(60.98M)(55.35M)(16.71M)(29.17M)
EBITDA Margin-1494.0%-116.9%-44.5%-5.0%-7.2%
Operating Income(154.35M)(63.76M)(63.28M)(27.95M)(40.98M)
Operating Margin-1528.6%-122.2%-50.8%-8.4%-10.1%
Interest Income00000
Interest Expense4.5M5.07M8.87M20.09M28.4M
Other Income / Expenses(3.82M)(3.44M)(2.24M)(10.92M)(19.65M)
Income Before Tax(158.16M)(67.2M)(65.52M)(38.87M)(60.63M)
Pre-Tax Margin-1566.4%-128.8%-52.6%-11.7%-14.9%
Income Tax Expense4K8K547K266K969K
Net Income(158.17M)(67.21M)(66.07M)(39.14M)(61.6M)
Net Margin-1566.5%-128.9%-53.1%-11.7%-15.1%
EPS (Basic)(1.52)(0.42)(0.30)(0.17)(0.26)
EPS (Diluted)(1.52)(0.42)(0.30)(0.17)(0.26)
Weighted Avg Shares104.21M158.69M219.33M235.23M241.03M
Weighted Avg Shares (Diluted)104.21M158.69M219.33M235.23M241.03M

Ardelyx, Inc.

NASDAQ:ARDX

Intrinsic Alpha fair value

Locked

Current Price

$3.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.